Compare Twist Bioscience Corp (TWST) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs United Airlines Holdings Inc — how do they compare? Twist Bioscience Corp trades at $152.84 (market cap $10.08B), while United Airlines Holdings Inc trades at $106.5 (market cap $34.87B). The key difference: United Airlines Holdings Inc is far larger — about 3.5× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and United Airlines Holdings Inc for 46 Days on average.
| TWST | UAL | |
|---|---|---|
Market Cap | $10.08B | $34.87B |
Volume | 4,229,037 | 6,329,678 |
Sector | Health | Industrials |
52-Week High | $205.00 | $136.11 |
52-Week Low | $25.45 | $85.21 |
Typical Hold Time | 27 Days | 46 Days |
Enterprise Value | $10.01B | $51.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
United Airlines (UAL) trades at $110.17, down 1.53% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.06, net income margin of 5.56%, and three consecutive quarterly EPS beats. Recent news highlights aggressive customer acquisition tactics targeting Delta's elite travelers with status-match offers and Starlink WiFi advantages.
Outlook remains positive given analyst consensus of $158.10 price target and 66% buy ratings, but risks include rising fuel costs, labor expenses, and competitive pressures. Earnings growth and market share gains are key catalysts, though near-term volatility persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
